25th April 2019, Libourne – ForcerisTM received the first marketing authorisation from the European Medicines Agency (EMA) for this innovative combination of gleptoferron and toltrazuril to treat neonatal piglets.

Forceris^TM is indicated for the prevention of iron deficiency anaemia, treatment of coccidiosis (diarrhoea), as well as helping to prevent the occurrence of coccidiosis, by reducing oocyst excretion on farms with a confirmed history of the disease caused by Cystoisospora suis. Forceris^TM is a fixed dose combination product and will be available in two different presentations of 100ml and 250 ml.

Coccidiosis is a common cause of piglet diarrhoea, resulting in scouring and severe discomfort in neo-natal piglets, which if left untreated can be fatal. Infection can occur in all types of farrowing facilities and under all types of management systems.

Iron deficiency anaemia in piglets is well known and treatment with iron supplementation is common practice in most modern pig rearing systems. Piglets are born with very little reserve of iron and with colostrum and milk from the sow usually providing only 15% or less of their daily requirement for optimal growth and development, further supplementation is essential.

Forceris^TM is the new, easy-to-use combination product that allows the prevention and treatment of these two major problems in lactating piglets from the first day of life.

=>>For more information, please contact your local Ceva representative.

- ends -

PDF available here: 2019-04-25_Forceris launch_EN.pdf